Laronidasa

Laronidasa Uses, Dosage, Side Effects, Food Interaction and all others data.

Human recombinant alpha-L-iduronidase, 628 residues (mature form), produced by recombinant DNAtechnology in a Chinese hamster ovary cell line. Laronidasa is a glycoprotein with a molecular weight of approximately 83 kD. The predicted amino acid sequence of the recombinant form, as well as the nucleotide sequence that encodes it, are identical to a polymorphic form of human a-L-iduronidase. It contains 6 N-linked oligosaccharide modification sites.

Laronidasa is used to treat mucopolysaccharide storage disorders (specifically mucopolysaccharidosis 1 or Hurlers syndrome) caused by deficiencies of alpha-L-iduronidase. Reduced or absent a-L-iduronidase activity results in the accumulation of the GAG substrates, dermatan sulfate and heparan sulfate, throughout the body and leads to widespread cellular, tissue, and organ dysfunction.

Laronidasa
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Laronidasa
Availability	Prescription only
Generic	Laronidase
Laronidase Other Names	alpha-L-Idosiduronase, Human Recombinant alpha-L-iduronidase, Laronidasa, Laronidase, Laronidase (genetical recombination)
Related Drugs	Aldurazyme
Type
Formula	C₃₁₆₀H₄₈₄₈N₈₉₈O₈₈₁S₁₂
Weight	69899.4 Da
Groups	Approved
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

Laronidasa is a form of recombinant human alpha-L-iduronidase used to treat Hurler and Hurler-Scheie forms of mucopolysaccharidosis, a genetic deficiency of alpha-L-iduronidase.

For the treatment of mucopolysaccharidosis

Laronidasa is also used to associated treatment for these conditions: Type 1 Mucopolysaccharidosis